

# Michael A Postow

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4008252/publications.pdf>

Version: 2024-02-01

140  
papers

45,828  
citations

15466

65  
h-index

15218

126  
g-index

143  
all docs

143  
docs citations

143  
times ranked

43405  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015, 373, 23-34.	13.9	6,773
2	Nivolumab plus Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2013, 369, 122-133.	13.9	3,776
3	Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 2189-2199.	13.9	3,753
4	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1345-1356.	13.9	3,589
5	Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. <i>New England Journal of Medicine</i> , 2018, 378, 158-168.	13.9	3,047
6	Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015, 372, 2006-2017.	13.9	2,489
7	Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma. <i>New England Journal of Medicine</i> , 2012, 366, 925-931.	13.9	1,836
8	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. <i>Lancet</i> , The, 2014, 384, 1109-1117.	6.3	1,588
9	T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. <i>Nature</i> , 2017, 545, 60-65.	13.7	1,280
10	OncokB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	1.5	1,266
11	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. <i>New England Journal of Medicine</i> , 2018, 379, 722-730.	13.9	983
12	Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. <i>Journal of Clinical Oncology</i> , 2015, 33, 3193-3198.	0.8	892
13	Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 709-717.	0.8	829
14	Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1558-1568.	5.1	827
15	Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors. <i>JAMA Oncology</i> , 2016, 2, 1346.	3.4	667
16	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2016, 22, 5487-5496.	3.2	480
17	Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016, 22, 2908-2918.	3.2	459
18	Immune Modulation in Cancer with Antibodies. <i>Annual Review of Medicine</i> , 2014, 65, 185-202.	5.0	455

#	ARTICLE	IF	CITATIONS
19	MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	425
20	Targeting T Cell Co-receptors for Cancer Therapy. <i>Immunity</i> , 2016, 44, 1069-1078.	6.6	418
21	Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 3807-3814.	0.8	364
22	Managing Immune Checkpoint-Blocking Antibody Side Effects. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 76-83.	1.8	344
23	Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology Statement. <i>Journal of Clinical Oncology</i> , 2015, 33, 3826-3833.	0.8	343
24	Stereotactic Radiosurgery for Melanoma Brain Metastases in Patients Receiving Ipilimumab: Safety Profile and Efficacy of Combined Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 368-375.	0.4	334
25	LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer. <i>Cell</i> , 2018, 172, 825-840.e18.	13.5	312
26	Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. <i>Cancer Immunology Research</i> , 2016, 4, 383-389.	1.6	247
27	The efficacy of anti-PD-1 agents in acral and mucosal melanoma. <i>Cancer</i> , 2016, 122, 3354-3362.	2.0	236
28	Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. <i>Cancer Treatment Reviews</i> , 2017, 58, 70-76.	3.4	228
29	Checkpoint blocking antibodies in cancer immunotherapy. <i>FEBS Letters</i> , 2014, 588, 368-376.	1.3	227
30	The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma. <i>Clinical Infectious Diseases</i> , 2016, 63, 1490-1493.	2.9	226
31	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	13.5	223
32	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , 2021, 27, 1432-1441.	15.2	216
33	Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. <i>Oncologist</i> , 2016, 21, 1230-1240.	1.9	212
34	Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. <i>Nature Communications</i> , 2021, 12, 729.	5.8	212
35	Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. <i>Nature</i> , 2015, 526, 453-457.	13.7	191
36	Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma. , 2015, 3, 23.		190

#	ARTICLE	IF	CITATIONS
37	Rational design of anti-GITR-based combination immunotherapy. <i>Nature Medicine</i> , 2019, 25, 759-766.	15.2	180
38	CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. <i>Frontiers in Oncology</i> , 2014, 4, 385.	1.3	175
39	Clinical activity of ipilimumab for metastatic uveal melanoma. <i>Cancer</i> , 2013, 119, 3687-3695.	2.0	171
40	First-in-Humans Imaging with <sup>89</sup> Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting. <i>Journal of Nuclear Medicine</i> , 2020, 61, 512-519.	2.8	170
41	Treatment Outcomes of Immune-Related Cutaneous Adverse Events. <i>Journal of Clinical Oncology</i> , 2019, 37, 2746-2758.	0.8	160
42	Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 391-398.	0.8	156
43	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	5.1	155
44	Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. <i>Oncologist</i> , 2016, 21, 848-854.	1.9	154
45	Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016, 22, 4848-4858.	3.2	146
46	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. <i>Cell Research</i> , 2015, 25, 208-224.	5.7	143
47	Combinations of Radiation Therapy and Immunotherapy for Melanoma: A Review of Clinical Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 986-997.	0.4	142
48	Ipilimumab for Patients With Advanced Mucosal Melanoma. <i>Oncologist</i> , 2013, 18, 726-732.	1.9	140
49	The association between tumor mutational burden and prognosis is dependent on treatment context. <i>Nature Genetics</i> , 2021, 53, 11-15.	9.4	139
50	Mucosal Melanoma: Pathogenesis, Clinical Behavior, and Management. <i>Current Oncology Reports</i> , 2012, 14, 441-448.	1.8	138
51	Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade. <i>Journal of Clinical Oncology</i> , 2020, 38, 1655-1663.	0.8	138
52	On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. <i>Science Translational Medicine</i> , 2015, 7, 280sr1.	5.8	134
53	Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma. <i>Cancer Immunology Research</i> , 2013, 1, 92-98.	1.6	133
54	Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1692-1704.	5.1	129

#	ARTICLE	IF	CITATIONS
55	Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma. <i>JAMA Oncology</i> , 2018, 4, 98.	3.4	125
56	Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes. <i>Cancer Immunology Research</i> , 2014, 2, 812-821.	1.6	122
57	Non-conventional Inhibitory CD4 <sup>+</sup> Foxp3 <sup>+</sup> PD-1 <sup>hi</sup> T Cells as a Biomarker of Immune Checkpoint Blockade Activity. <i>Cancer Cell</i> , 2018, 33, 1017-1032.e7.	7.7	112
58	Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. , 2017, 5, 8.		111
59	Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. <i>Nature Biotechnology</i> , 2022, 40, 499-506.	9.4	110
60	Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3925-3930.	1.8	106
61	Opportunistic infections in patients treated with immunotherapy for cancer. , 2014, 2, 19.		98
62	Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment. , 2017, 5, 76.		96
63	Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy. <i>Ophthalmology</i> , 2017, 124, 1788-1798.	2.5	95
64	High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy. <i>Cancer</i> , 2020, 126, 76-85.	2.0	92
65	Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. <i>Cancer Medicine</i> , 2018, 7, 690-697.	1.3	90
66	Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. <i>European Journal of Cancer</i> , 2017, 73, 61-70.	1.3	88
67	Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors. <i>Clinical Infectious Diseases</i> , 2020, 70, 193-199.	2.9	86
68	Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment. <i>EBioMedicine</i> , 2017, 18, 56-61.	2.7	83
69	Ipilimumab in patients with melanoma and autoimmune disease. , 2014, 2, 35.		82
70	Immune checkpoint modulation: Rational design of combination strategies. , 2015, 150, 23-32.		76
71	Health-related quality of life results from the phase III CheckMate 067 study. <i>European Journal of Cancer</i> , 2017, 82, 80-91.	1.3	76
72	Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). <i>Neuro-Oncology</i> , 2021, 23, 1961-1973.	0.6	66

#	ARTICLE	IF	CITATIONS
73	Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response. <i>Head and Neck</i> , 2016, 38, 1310-1317.	0.9	65
74	Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw260.	3.0	56
75	Immune checkpoint inhibitors to treat cutaneous malignancies. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1239-1253.	0.6	56
76	Proportions of blood-borne VÎ1+ and VÎ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , 2016, 64, 116-126.	1.3	54
77	LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	54
78	Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibitionâ€”A Pooled Analysis of Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3350-3358.	0.8	52
79	Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications. <i>Clinical Sarcoma Research</i> , 2012, 2, 16.	2.3	49
80	Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis. <i>JAMA Oncology</i> , 2022, 8, 385.	3.4	44
81	Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies. <i>Cancer</i> , 2021, 127, 2062-2073.	2.0	40
82	Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition. <i>Current Oncology Reports</i> , 2016, 18, 21.	1.8	39
83	Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma. <i>Melanoma Research</i> , 2017, 27, 57-64.	0.6	39
84	Elevated Blood Neutrophil-to-Lymphocyte Ratio: A Readily Available Biomarker Associated with Death due to Disease in High Risk Nonmetastatic Melanoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 1989-1996.	0.7	39
85	Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. <i>Annals of Surgical Oncology</i> , 2020, 27, 1180-1188.	0.7	39
86	Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature. <i>Oncologist</i> , 2020, 25, 140-149.	1.9	38
87	Checkpoint Blockade for the Treatment of Advanced Melanoma. <i>Cancer Treatment and Research</i> , 2016, 167, 231-250.	0.2	36
88	Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience. <i>Oncologist</i> , 2019, 24, e196-e197.	1.9	31
89	Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition. , 2022, 10, e004008.		28
90	The Antitumor Immunity of Ipilimumab: (T-cell) Memories to Last a Lifetime?. <i>Clinical Cancer Research</i> , 2012, 18, 1821-1823.	3.2	27

#	ARTICLE	IF	CITATIONS
91	A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 3193-3201.	3.2	27
92	Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. , 2021, 9, e001884.		27
93	Beyond Cancer Vaccines. <i>Cancer Journal (Sudbury, Mass )</i> , 2011, 17, 372-378.	1.0	26
94	Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study). <i>Journal of Clinical Oncology</i> , 2022, 40, 1059-1067.	0.8	26
95	The need for a network to establish and validate predictive biomarkers in cancer immunotherapy. <i>Journal of Translational Medicine</i> , 2017, 15, 223.	1.8	25
96	Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas. <i>Clinical Cancer Research</i> , 2021, 27, 2226-2235.	3.2	25
97	Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2012, 18, 153-9.	1.0	25
98	Safety of Infusing Ipilimumab Over 30 Minutes. <i>Journal of Clinical Oncology</i> , 2015, 33, 3454-3458.	0.8	24
99	Imaging findings of immune checkpoint inhibitor associated pancreatitis. <i>European Journal of Radiology</i> , 2020, 131, 109250.	1.2	24
100	Intravitreal Cutaneous Metastatic Melanoma in the Era of Checkpoint Inhibition. <i>Ophthalmology</i> , 2020, 127, 240-248.	2.5	22
101	Checkpoint Modulation in Melanoma: An Update on Ipilimumab and Future Directions. <i>Current Oncology Reports</i> , 2013, 15, 500-508.	1.8	20
102	Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab. <i>Melanoma Research</i> , 2020, 30, 71-75.	0.6	20
103	Liver resection and ablation for metastatic melanoma: A single center experience. <i>Journal of Surgical Oncology</i> , 2015, 111, 962-968.	0.8	19
104	A phase II study to evaluate the need for > two doses of nivolumab + ipilimumab combination (combo) immunotherapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10003-10003.	0.8	19
105	Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with <i>NRAS</i> -mutant Melanoma. <i>Clinical Cancer Research</i> , 2022, 28, 3002-3010.	3.2	18
106	Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab. <i>Journal of Translational Medicine</i> , 2014, 12, O8.	1.8	17
107	Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphenylprone to immune checkpoint inhibitor treatment. <i>Experimental Dermatology</i> , 2016, 25, 553-554.	1.4	17
108	Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-oncology Research. <i>Clinical Cancer Research</i> , 2018, 24, 730-736.	3.2	16



#	ARTICLE	IF	CITATIONS
109	A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC-X Trial).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS9600-TPS9600.	0.8	16
110	Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. , 2022, 10, e003853.		16
111	Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center. <i>British Journal of Haematology</i> , 2015, 171, 84-90.	1.2	14
112	Patient perspectives on ipilimumab across the melanoma treatment trajectory. <i>Supportive Care in Cancer</i> , 2017, 25, 2155-2167.	1.0	14
113	Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067. , 2021, 9, e003743.		14
114	Computed tomography-derived assessments of regional muscle volume: Validating their use as predictors of whole body muscle volume in cancer patients. <i>British Journal of Radiology</i> , 2018, 91, 20180451.	1.0	12
115	Evaluation of the Response of Unresectable Primary Cutaneous Melanoma to Immunotherapy Visualized With Reflectance Confocal Microscopy. <i>JAMA Dermatology</i> , 2019, 155, 347.	2.0	12
116	A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. <i>Oncolmmunology</i> , 2021, 10, 1898105.	2.1	11
117	Facts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse Events. <i>Clinical Cancer Research</i> , 2022, 28, 1250-1257.	3.2	11
118	Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation. <i>Oncotarget</i> , 2017, 8, 105000-105010.	0.8	10
119	Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 810388.	2.2	9
120	TNF± Blockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly?. <i>Clinical Cancer Research</i> , 2020, 26, 2085-2086.	3.2	8
121	Recommendations for Testing and Treating Outpatient Cancer Patients in the Era of COVID-19. <i>Journal of the National Cancer Institute</i> , 2021, 113, 820-822.	3.0	7
122	Markers for Anti-cytotoxic T-lymphocyte Antigen 4 (CTLA-4) Therapy in Melanoma. <i>Methods in Molecular Biology</i> , 2014, 1102, 83-95.	0.4	7
123	Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab. , 2021, 9, e003395.		7
124	A step forward for patients with NRAS-mutant melanoma. <i>Lancet Oncology</i> , The, 2017, 18, 414-415.	5.1	6
125	The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas. <i>Clinical Cancer Research</i> , 2021, 27, 1516-1525.	3.2	6
126	Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma. <i>Cancers</i> , 2022, 14, 2300.	1.7	6



#	ARTICLE	IF	CITATIONS
127	Current options and future directions in the systemic treatment of metastatic melanoma. <i>Journal of Community and Supportive Oncology</i> , 2014, 12, 20-26.	0.1	5
128	Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series. <i>Oncologist</i> , 2022, 27, e350-e352.	1.9	4
129	The brim of uncertainty in adjuvant treatment of melanoma. <i>Lancet Oncology</i> , The, 2018, 19, 436-437.	5.1	3
130	Immune-Directed Molecular Imaging Biomarkers. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 584-603.	2.5	3
131	Dermatologic infections in cancer patients treated with checkpoint inhibitors. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 1528-1536.	0.6	3
132	Targeting immune checkpoints in melanoma: an update. <i>Melanoma Management</i> , 2015, 2, 339-352.	0.1	2
133	Reduced-dose ipilimumab with standard-dose pembrolizumab: is less more?. <i>Lancet Oncology</i> , The, 2017, 18, 1144-1145.	5.1	2
134	Chemotherapy in the Rwandan Countryside: Universal Issues a World Away. <i>Annals of Internal Medicine</i> , 2012, 156, 60.	2.0	1
135	Reply to M. Horiguchi et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 721-721.	0.8	1
136	The Ice Cream Man. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1518.	3.8	0
137	Reply to A. Indini et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 1018-1019.	0.8	0
138	Primary Mucosal Melanomas of the Head and Neck. , 2016, , 641-656.		0
139	The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021. <i>Journal of Translational Medicine</i> , 2022, 20, 179.	1.8	0
140	Melanoma-Specific Clinical Outcomes of Inpatient Immune Checkpoint Blockade Treatment. <i>Oncologist</i> , 0, , .	1.9	0